Resumo Introdução: A mifepristona é um antagonista da progesterona frequentemente utilizado na interrupção médica da gravidez. Um dos seus alvos é o corpo lúteo, a principal fonte de progesterona na manutenção da gravidez inicial. O volume do corpo lúteo relaciona-se com os níveis séricos de progesterona. Objetivo: Este estudo teve como objetivo avaliar a existência de associação entre o volume do corpo lúteo e a taxa de sucesso da interrupção farmacológica da gravidez com mifepristona e misoprostol. Métodos: Este foi um estudo prospetivo, longitudinal e observacional. Foram incluídas 176 mulheres com intenção de interromper a gravidez. Na primeira consulta médica foi confirmada a presença de uma gravidez viável com menos de 10 semanas e estimado o volume do corpo lúteo por ecografia transvaginal. O protocolo de interrupção médica da gravidez no nosso hospital consistiu na administração de mifepristona oral 200 mg seguida (24 horas) de misoprostol oral 200 µg um comprimido a cada hora até ao máximo de oito doses. Na consulta de reavaliação foram registados dados clínicos e confirmado o sucesso do procedimento por ecografia vaginal. Resultados: A taxa de sucesso da interrupção médica da gravidez foi de 95,5%. Não foram observadas diferenças no volume do corpo lúteo entre os grupos de sucesso e insucesso da interrupção da gravidez. Conclusão: Nesta amostra no houve associação entre o volume do corpo lúteo e a taxa de sucesso da interrupção médica da gravidez.

Abstract Background: Mifepristone is a progesterone antagonist often used in medical termination of pregnancy. One of its targets is the corpus luteum, the main source of progesterone in initial pregnancy maintenance. Corpus luteum volume is related to serum progesterone levels. Objective: This study intended to evaluate whether there is an association between corpus luteum volume and the success rate of pharmacological termination of pregnancy with mifepristone and misoprostol. Methods: This was a prospective, longitudinal, observational study. 176 women deciding to terminate their pregnancy were included. At the first medical visit we confirmed the presence of a viable pregnancy with less than 10 weeks and estimated corpus luteum volume by transvaginal ultrasound. Medical termination of pregnancy protocol in our hospital consisted of oral mifepristone 200 mg followed (24 hours) by oral misoprostol 200 µg one pill every hour until a maximum of eight doses. At the reevaluation visit, we registered clinical data and confirmed the success of the procedure by vaginal ultrasound. Results: The success rate of medical termination of pregnancy was 95.5%. No differences regarding corpus luteum volume were observed between successful and unsuccessful termination of pregnancy groups. Conclusion: In our sample there was no association between corpus luteum volume and the success rate of medical termination of pregnancy.

Abstract The authors present a case of subchorionic placental cysts associated with fetal growth restriction and intracystic hemorrhage in the third trimester. In general, placental surface cysts are small and remain uneventful during pregnancy. However, larger cysts and cysts near the umbilical cord may be associated with adverse neonatal outcomes. It is therefore essential to recognize situations that may require an individualized approach.

Abstract Introduction Malignant mesonephric tumors are uncommon in the female genital tract, and they are usually located where embryonic remnants of Wolffian ducts are detected, such as the uterine cervix. The information about these tumors, their treatment protocol, and prognosis are scarce. Case report A 60-year-old woman with postmenopausal vaginal bleeding was initially diagnosed with endometrial carcinoma. After suspicion co-testing, the patient underwent a loop electrosurgical excision of the cervix and was eventually diagnosed with mesonephric adenocarcinoma. She was subjected to a radical hysterectomy, which revealed International Federation of Gynecology and Obstetrics (FIGO) IB1 stage, and adjuvant radiotherapy. The follow-up showed no evidence of recurrence after 60 months. Conclusion We present the case of a woman with cervical mesonephric adenocarcinoma. When compared with the literature, this case had the longest clinical follow-up without evidence of recurrence, which reinforces the concept that these tumors are associated with a favorable prognosis if managed according to the guidelines defined for the treatment of patients with cervical adenocarcinomas. Though a rare entity, it should be kept in mind as a differential diagnosis for other cervical cancers.